Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1-7 via PI3K/AKT/mTOR Signaling Pathway.

MLA

Ahmed, Yasmin M., et al. “Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1-7 via PI3K/AKT/MTOR Signaling Pathway.” Pharmaceuticals (Basel, Switzerland), vol. 15, no. 3, Mar. 2022. EBSCOhost, https://doi.org/10.3390/ph15030341.

APA

Ahmed, Y. M., Abdelgawad, M. A., Shalaby, K., Ghoneim, M. M., AboulMagd, A. M., Abdelwahab, N. S., Hassan, H. M., & Othman, A. M. (2022). Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1-7 via PI3K/AKT/mTOR Signaling Pathway. Pharmaceuticals (Basel, Switzerland), 15(3). https://doi.org/10.3390/ph15030341

Chicago

Ahmed, Yasmin M, Mohamed A Abdelgawad, Khaled Shalaby, Mohammed M Ghoneim, Asmaa M AboulMagd, Nada S Abdelwahab, Hossam M Hassan, and Asmaa M Othman. 2022. “Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1-7 via PI3K/AKT/MTOR Signaling Pathway.” Pharmaceuticals (Basel, Switzerland) 15 (3). doi:10.3390/ph15030341.